title: Systemic vasculitis.
abstract: The systemic vasculitides are characterized by inflammation of blood vessel walls. Vessels of any type, in any organ can be affected, resulting in a broad spectrum of signs and symptoms. The heterogenous nature of vasculitides presents a diagnostic challenge. The American College of Rheumatology classification criteria and the Chapel Hill Consensus Conference nomenclature are the most widely used to distinguish different forms of vasculitis. The Chapel Hill Consensus Conference nomenclature defines 10 primary vasculitides based on vessel size (large, medium, and small). The diagnosis relies on the recognition of a compatible clinical presentation supported by specific laboratory or imaging tests and confirmatory histology. Antineutrophilic cytoplasmic antibody testing has been of particular benefit in defining a subgroup of small vessel vasculitides. Treatment is based on clinical presentation and the pattern of organ involvement. Glucocorticoids are the primary treatment for many forms of vasculitis. Additional immunosuppressive agents, including methotrexate and cyclophosphamide, are sometimes required. Newer approaches, such as the use of anti-tumor necrosis factor or B cell therapies, are being tried in resistant cases. Patients can experience considerable treatment-related toxicity, especially infection from immunosuppressive therapy and adverse effects from steroids (e.g., osteoporosis, diabetes mellitus, cataract). Vitamin D and calcium prophylaxis are recommended in patients on long-term steroid therapy.
authors.affiliation: Creighton University Medical Center, Omaha, NE 68131, USA.
authors.forename: Poonam
authors.initials: P
authors.lastname: Sharma
authors.forename: Sanjeev
authors.initials: S
authors.lastname: Sharma
authors.forename: Richard
authors.initials: R
authors.lastname: Baltaro
authors.forename: John
authors.initials: J
authors.lastname: Hurley
mesh_terms: D003520:Cyclophosphamide / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D056647:Systemic Vasculitis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000473:pathology
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D008727:Methotrexate